Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.66 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.65 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.65 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.59 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.53 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772855 | 0.88 | FFAR1 (0.83) | FFAR1CYP4F2CYP4A11NR4A2FFAR4 | |
| SCHEMBL7998538 | 0.88 | FFAR1 (0.69) | FFAR1CYP4F2CYP4A11NR4A2MAOB | |
| SCHEMBL11400956 | 0.87 | FFAR1 (0.64) | FFAR1CYP4F2CYP4A11FFAR4 | |
| SCHEMBL2036020 | 0.86 | FFAR1 (0.76) | FFAR1FFAR4PARP10 | |
| SCHEMBL3660617 | 0.85 | FFAR1 (0.66) | FFAR1CYP4F2CYP4A11NR4A2MAOB | |
| SCHEMBL12618315 | 0.85 | FFAR1 (0.66) | FFAR1CYP4F2CYP4A11NR4A2MAOB | |
| SCHEMBL2848980 | 0.84 | NR4A2 (0.62) | FFAR1CYP4F2CYP4A11SPHK2SPHK1 | |
| SCHEMBL2170636 | 0.84 | FFAR1 (0.77) | FFAR1NR4A2FFAR4PARP10 | |
| SCHEMBL2908859 | 0.84 | FFAR1 (0.64) | FFAR1CYP4F2CYP4A11NR4A2MAOB | |
| SCHEMBL10683288 | 0.82 | FFAR1 (0.63) | FFAR1CYP4F2CYP4A11NR4A2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2220077-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009080730-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080730-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SSB, RORC, OXA1L | FFAR1 1971/4885CYP4F2 664/4885CYP4A11 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.